Ketamine was identified as a potential rapid-acting antidepressant more than two decades ago — yet most people suffering from treatment-resistant depression in Toledo and across northwest Ohio have never had a real conversation about it with a provider. The gap between the evidence and what patients are actually offered has cost years of quality of life for people who deserved a different option sooner. At Awakenings by Northwest Ohio Ketamine, we exist specifically to close that gap, offering IV ketamine infusion therapy under the clinical leadership of Dr. William James, MD, whose background in anesthesiology gives our team a depth of expertise in this treatment that is uncommon in the region.
What IV Ketamine Is and How It Works
Ketamine is an anesthetic agent that has been used safely in operating rooms for decades. Its use in psychiatry represents an off-label application — meaning it has not received FDA approval specifically for the treatment of depression or other psychiatric conditions, and patients should understand that distinction clearly before beginning treatment. What has accumulated since the landmark 2000 randomized controlled trial by Berman and colleagues is an extensive body of clinical and mechanistic research demonstrating rapid, meaningful reductions in depressive symptoms following IV ketamine infusions — often within hours to days, compared to the four-to-six-week timeline of standard antidepressants.
Ketamine’s primary mechanism in the context of mood disorders involves antagonism of NMDA receptors — a subtype of glutamate receptor that plays a central role in synaptic plasticity and neuroplasticity. By blocking these receptors, ketamine appears to trigger a downstream cascade of events including increased AMPA receptor signaling, BDNF (brain-derived neurotrophic factor) release, and activation of mTOR signaling pathways — all of which support the formation of new synaptic connections. This synaptic renewal hypothesis helps explain ketamine’s antidepressant effects and why they appear quickly: rather than slowly shifting monoamine neurotransmitter levels over weeks, ketamine activates cellular machinery that rebuilds neural connections more directly and rapidly.
A systematic review and meta-analysis published in Bipolar Disorders found that a single IV ketamine infusion produced significant antidepressant effects within 24 hours in patients with major depressive disorder or bipolar depression, with response rates significantly higher than control conditions (Romeo et al., 2015). The challenge with ketamine’s antidepressant effects is their duration — benefits typically last days to weeks from a single infusion, which is why standard clinical protocols use a series of six infusions over two to three weeks for induction, followed by maintenance infusions at longer intervals for patients who respond. To better understand the science behind ketamine therapy and how it works in the brain, our research-backed overview goes deeper into the neurobiological mechanisms at play.
How We Administer IV Ketamine at Awakenings
At Awakenings by Northwest Ohio Ketamine in Toledo, IV ketamine infusions are administered in a supervised clinical environment by a team with deep anesthesiology expertise. Dr. William James, MD, leads our clinical operations, and his background in anesthesiology and pain management means that ketamine — a drug whose pharmacological profile he has known intimately for decades — is administered here with a degree of procedural sophistication that outpatient psychiatric clinics are not always positioned to match.
The standard induction protocol involves six IV ketamine infusions administered over two to three weeks. Each infusion typically lasts 40 to 60 minutes, with additional monitoring time before and after the infusion. The dose is typically sub-anesthetic — enough to produce the neuroplasticity-related effects associated with mood improvement without inducing full anesthesia. During the infusion, patients may experience dissociative effects including altered perception of time and space, visual distortions, and a sense of detachment from surroundings. These experiences vary in intensity from patient to patient and are monitored closely throughout. Our team is present and attentive during every infusion.
Integration coaching — a service we provide at Awakenings specifically for ketamine patients — is an important companion to the infusion process itself. Research and clinical experience suggest that the period following ketamine infusions is a window of heightened neuroplasticity during which patients may be unusually receptive to behavioral and psychological change. Integration coaching provides structured support to help patients use that window productively — to process insights, establish new behavioral patterns, and engage with the broader work of recovery. Results vary by individual, and we encourage every patient beginning IV ketamine to engage with integration support.
Who Is IV Ketamine For
IV ketamine is most appropriate for patients with treatment-resistant depression — typically defined as inadequate response to two or more antidepressant medications of adequate dose and duration — and for patients with significant depressive symptoms in the context of other mood disorders, including PTSD and anxiety, who have not found adequate relief through conventional approaches. At Awakenings, we treat mental health conditions including treatment-resistant depression, major depressive disorder, PTSD, anxiety, OCD, and bipolar depression, as well as chronic pain conditions — Dr. James’s dual expertise in anesthesiology and pain management makes our clinic uniquely suited to treating patients whose mental health and pain conditions are intertwined.
Before initiating IV ketamine, our team conducts a thorough clinical evaluation to confirm candidacy and rule out contraindications. Ketamine is not appropriate for patients with active psychosis, uncontrolled hypertension, or certain cardiovascular conditions, among other exclusions. Dissociative disorders require careful evaluation before ketamine is considered. We take candidacy seriously, and we will be straightforward with you about whether IV ketamine is an appropriate option for your specific situation based on your full medical and psychiatric history.
Addressing Common Questions and Barriers
Cost is one of the most common concerns we hear from prospective patients. IV ketamine for psychiatric indications is generally not covered by commercial insurance, which means most patients pay out of pocket for the infusion series. At Awakenings, we provide transparent pricing before you commit to anything, and we are happy to discuss payment options. The cost of a full infusion series should be weighed in the context of the alternatives — years of ineffective medication trials, lost productivity, and reduced quality of life are also costs, even if they are harder to quantify.
Some patients are concerned about the dissociative effects during the infusion itself and want to know what to expect. We spend time before your first infusion explaining the experience as specifically as possible — what the dissociation typically feels like, how long it lasts, and how our team will be present with you throughout. Many patients find the experience unexpectedly profound or even peaceful; others find it disorienting. Discuss with your provider what you have heard and what concerns you have so we can address them directly before you begin. Results vary by individual, and no two infusion experiences are identical. You can also read about Ohio ketamine treatment and what to expect to help you feel more prepared going into your first visit.
Frequently Asked Questions
Is IV ketamine FDA-approved for depression?
No. IV ketamine for psychiatric purposes — including depression, PTSD, and anxiety — is an off-label use of a medication that was FDA-approved as an anesthetic. Off-label prescribing is common and legal in medicine, and the clinical evidence for IV ketamine in treatment-resistant depression is substantial. However, patients should understand that off-label use means the FDA has not specifically evaluated and approved ketamine for these indications.
How many infusions will I need?
The standard induction protocol is six infusions over two to three weeks. Not all patients respond after the full induction series, but many who do respond experience meaningful symptom relief that persists beyond the infusion period. Patients who respond to induction may benefit from periodic maintenance infusions to sustain the effect — the frequency varies by patient. We discuss maintenance planning with every patient who completes induction.
Will IV ketamine interact with my current medications?
Some medications require evaluation before IV ketamine is initiated, including benzodiazepines, opioids, and certain antidepressants. Our clinical team reviews your full medication list before your first infusion and will advise you on any modifications that may be needed. Do not stop or change any medications before consulting with our team.
Is ketamine addictive?
Ketamine is a schedule III controlled substance and carries potential for abuse and dependence at recreational doses. At the sub-anesthetic doses and controlled intervals used in clinical IV ketamine protocols, the risk of dependence is significantly lower, though it is not zero. Our team monitors for signs of problematic use and structures treatment to minimize risk. Patients with a personal or family history of substance use disorders should disclose this during their evaluation so it can be factored into candidacy assessment. For more on this topic, see our post on whether ketamine is addictive when used for depression.
What does integration coaching involve, and is it required?
Integration coaching at Awakenings involves structured sessions with a coach trained in the post-ketamine integration process — helping patients articulate and work with any insights or shifts that arose during infusions and apply them constructively to their daily life and recovery. It is not required, but we strongly encourage it for patients undergoing a ketamine infusion series, as the neuroplasticity window following infusions represents a meaningful opportunity for change that is best supported by intentional guidance.
Key Takeaways
- IV ketamine is an off-label treatment for depression and other mood disorders that works through a fundamentally different mechanism than standard antidepressants, producing rapid reductions in depressive symptoms in many patients.
- At Awakenings by Northwest Ohio Ketamine in Toledo, IV ketamine is administered by a clinical team with deep anesthesiology expertise under the leadership of Dr. William James, MD.
- Standard IV ketamine induction involves six infusions over two to three weeks, followed by maintenance infusions for patients who respond.
- Integration coaching is offered at Awakenings to support patients during the neuroplasticity window following infusions and maximize the potential for lasting benefit.
- Results vary by individual; IV ketamine is not FDA-approved for psychiatric indications and is most appropriate for patients who have not found adequate relief through conventional treatments.
If you have been managing treatment-resistant depression, PTSD, or another mood disorder in the Toledo area and conventional treatment has not been enough, IV ketamine may represent a meaningfully different option worth exploring. Schedule a consultation with Dr. James and our team at Awakenings by Northwest Ohio Ketamine today.
About Dr. William James, MD
Dr. William James, MD, leads Awakenings by Northwest Ohio Ketamine in Toledo, OH, bringing a clinical background spanning anesthesiology and pain management to the treatment of chronic pain and mood disorders. The clinical team also includes Dr. Nadeem Moghal, who completed a fellowship at the Cleveland Clinic Foundation Pain Management Center, and Ben Wagner, PMHNP-BC, a board-certified Psychiatric Mental Health Nurse Practitioner — a multidisciplinary composition specifically designed to hold the pain, mood, cognitive, and functional dimensions of each patient’s condition in view simultaneously. Together, they approach chronic pain as a whole-person condition, integrating anesthesiology expertise with behavioral health in a way that most single-specialty practices cannot.
References
Romeo, B., et al. (2015). Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Research. https://pubmed.ncbi.nlm.nih.gov/26282316/
Berman, R. M., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. https://pubmed.ncbi.nlm.nih.gov/10686270/
National Institute of Mental Health. Depression. https://www.nimh.nih.gov/health/topics/depression
American Society of Ketamine Physicians, Psychotherapists & Practitioners. https://www.askp.org/
Medical Disclaimer
The information in this blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. IV ketamine for psychiatric conditions is an off-label use of a controlled substance and should only be pursued under the supervision of a licensed and qualified medical provider. Individual results vary. Whether IV ketamine is appropriate for any specific patient requires a thorough clinical evaluation. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.